Nature

Acute Cholangitis And Biliary Tract Infections

Acute cholangitis is a severe, bacterial infection of the biliary tract precipitated by an obstruction that often results in systemic inflammation and, in some cases, life‐threatening sepsis. This ...
Healio

VIDEO: Treatment outlook ‘rapidly changing’ in primary sclerosing cholangitis

Please provide your email address to receive an email when new articles are posted on . “Traditionally, we haven’t paid a lot of attention to symptoms in PSC, except when patients have acute ...
Business Insider

Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update

Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced plans for ...
Medscape

Elafibranor Appears Effective, Safe for Primary Biliary Cholangitis

Elafibranor, a dual peroxisome proliferator-activated receptor (PPAR) alpha and delta agonist, appears to be a safe and effective treatment of primary biliary cholangitis, according to a new clinical ...
Nasdaq

Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis

Planning for Phase 2 trial for moderate-to-severe chronic pruritus in primary biliary cholangitis (PBC) is ongoing and on track to initiate in 2024 BRIDGEWATER, NJ / ACCESSWIRE / June 10, 2024 / ...
Medscape

FDA Grants Livdelzi Accelerated Approval for Primary Biliary Cholangitis

The US Food and Drug Administration (FDA) granted accelerated approval for Livdelzi (seladelpar, Gilead Sciences, Inc.) for primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid ...
FOX59 News

Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update

Throughout 2024 Tharimmune achieved significant milestones across three key areas. These accomplishments reflect progress in advancing innovative therapies in inflammation and immunology, with a focus ...